普罗雌烯阴道胶丸不同给药方案治疗绝经后女性尿道综合征的临床研究

Clinical treatment of postmenopausal female urethral syndrome with promestriene vaginal gelatin capsules administered through different schemes

目的:观察普罗雌烯阴道胶丸局部应用时不同给药方案治疗绝经后女性尿道综合征的疗效及安全性。方法:选取慈溪市第三人民医院医疗健康集团总院2021年1月至2022年6月收治的绝经后女性尿道综合征患者120例为观察对象,采用随机数字表法分为治疗A组和B组,每组60例。治疗A组以普罗雌烯阴道胶丸10 mg阴道纳入,每天1次;治疗B组以普罗雌烯阴道胶丸10 mg阴道纳入,每天2次,两组均治疗20 d为一个疗程。比较两组症状改善情况、下尿路症状评分量表评分(LUTS)、生活质量评分(QOL)、血清雌二醇、促卵泡激素、子宫内膜厚度。结果:治疗后,A组尿不尽[(2.51±1.76)分]、排尿时间间隔[(2.66±1.08)分]、间断性排尿[(2.61±1.45)分]、憋尿困难[(2.48±1.42)分]、尿线变细[(2.85±1.03)分]、排尿用力程度[(2.48±1.42)分]和夜间排尿次数[(2.52±1.72)分]评分均显著低于B组[(3.15±1.35)分、(3.23±1.14)分、(2.99±1.57)分、(3.08±1.09)分、(3.45±1.72)分、(3.25±1.08)分、(3.21±1.87)分](t=10.57、9.78、13.83、10.34、9.35、12.34、9.45,均P<0.05);A组生活质量评分[(2.45±0.86)分]显著低于B组[(3.51±0.92)分](t=5.45,P<0.05)。两组治疗前后雌二醇、促卵泡激素及子宫内膜厚度比较,差异均无统计学意义(均P>0.05)。两组均无不良反应发生。结论:普罗雌烯阴道胶丸局部应用可改善绝经后女性尿道综合征症状,并且以10 mg阴道纳入,每天1次给药方案能取得更佳的疗效,且安全性佳。该研究具备显著创新性和科学性,值得临床推广使用。

ObjectiveTo investigate the efficacy and safety of promestriene vaginal gelatin capsules administered through different schemes in the treatment of postmenopausal female urethral syndrome.MethodsA total of 120 patients with postmenopausal female urethral syndrome who received treatment in General Hospital of Medical and Health Group of Cixi Third People's Hospital from January 2021 to June 2022 were included in this study.They were randomly divided into groups A and B(n=60/group).Group A was treated with vaginal gelatin capsules containing 10 mg promestriene once a day.Group B was treated with vaginal gelatin capsules containing 10 mg promestriene twice a day.Both groups were treated for 20 days as a course of treatment.The improvement of symptoms,lower urinary tract symptom score,quality of life score,estradiol level,follicle stimulating hormone level,and endometrial thickness were compared between the two groups.ResultsAfter treatment,the scores of incomplete urination,urination interval,intermittent urination,dysuria,thinner urine line,urination force,and nocturnal urination times in group A were(2.51±1.76)points,(2.66±1.08)points,(2.61±1.45)points,(2.48±1.42)points,(2.85±1.03)points,(2.48±1.42)points,and(2.52±1.72)points,respectively,which were significantly lower than(3.15±1.35)points,(3.23±1.14)points,(2.99±1.57)points,(3.08±1.09)points,(3.45±1.72)points,(3.25±1.08)points,and(3.21±1.87)points,respectively,in group B(t=10.57,9.78,13.83,10.34,9.35,12.34,9.45,all P<0.05).The quality of life score in group A was(2.45±0.86)points,which was significantly lower than(3.51±0.92)points in group B(t=5.45,P<0.05).There were no significant differences in estradiol and follicle stimulating hormone levels and endometrial thickness between the two groups before and after treatment(all P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups.ConclusionLocal application of promestriene vaginal gelatin capsules can improve the urethral syndrome in postmenopausal women.The once daily 10 mg promestriene vaginal gelatin capsule administration scheme can achieve better efficacy and safety than the twice daily administration scheme.The study is innovative,scientific,and worthy of clinical promotion.